Eli Lilly's Retatrutide Cuts Blood Sugar & Weight in Trial
Eli Lilly's triple-G drug retatrutide showed significant HbA1C and weight reductions in type 2 diabetes patients at 40 weeks in a 2026 late-stage trial.
GLP-1
2 articles tagged "GLP-1"
FDA Targets Telehealth GLP-1 Compounders in 2026 Crackdown
FDA has warned 70+ telehealth companies over compounded GLP-1 drugs, with scrutiny now extending to affiliated medical groups and prescribing networks.
By Robert Kim